Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease Save

Date Added
April 8th, 2020
PRO Number
Pro00099215
Researcher
Andrew Goodwin

List of Studies


Profiles_link
Keywords
Infectious Diseases, Lung, Pulmonary
Summary

This is a blinded, multicenter, placebo-controlled randomized clinical trial. In this trial, the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with COVID-19 will be evaluated. In this study, a medication called hydroxychloroquine is being investigated to see if it improves recovery from COVID-19 in patients admitted to the hospital. Hydroxychloroquine is used to treat malaria and some joint (rheumatologic) diseases, but it is unknown if it helps patients recover from COVID-19. Study medication will be given for 5 days. This medication could be either hydroxychloroquine or placebo. There will be up to 510 patients in the study at about 50 hospitals in the United States.

Institution
MUSC
Recruitment Contact
Abigail Grady
843-792-2072
gradyabi@musc.edu

Change_preferences

-- OR --

Create_login